IMPACT OF INITIAL RENAL INVOLVEMENT AND BENCE JONES PROTEINS IN THE URINE ON OVERALL SURVIVAL OF  PATIENTS WITH MULTIPLE MYELOMA

Svetlana Krstevska Balkanov; Sanja Trajkova; Aleksandra Pivkova Veljanovska; Dejan Spasovski; Nevenka Ridova; Goce Kalcev; Irina Panovska Stavridis

Svetlana Krstevska Balkanov University Clinic for Hematology, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, Skopje, Republic of North Macedonia
Sanja Trajkova University Clinic of Hematology, Faculty of Medicine, Ss Cyril and Methodius University in Skopje, Republic of North Macedonia
Aleksandra Pivkova Veljanovska University Clinic of Hematology, Faculty of Medicine, Ss Cyril and Methodius University in Skopje, Republic of North Macedonia
Dejan Spasovski University Clinic for Rheumatology, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, Republic of North Macedonia
Nevenka Ridova University Clinic for Hematology, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, Republic of North Macedonia
Goce Kalcev University of Cagliari, Cagliari, Italy
Irina Panovska Stavridis University Clinic for Hematology, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, Republic of North Macedonia

Abstract

Multiple myeloma (MM) is a cancer of plasma cells with a frequency of around 50 cases per million population (pmp)/year. This retrospective study was conducted at the University Clinic for Hematology in Skopje, North Macedonia, in the period between January 2009 and December 2019. The cohort group was consisted of 296 recently diagnosed patients with MM. According to the results of our study, in 47% of patients who did not have renal involvement (RI), the survival rate was more than 60 months. On the other side, the survival percentage in those patients who had ARI (acute renal impairment) was 9% and in those who had CRI (chronic renal impairment) only 10%. Forty percent of patients with a negative Bence Jones proteinuria survived more than 60 months. Besides, only 20% of patients with a positive Bence Jones proteinuria survived more than 60 months. Nowadays, bortezomib is generally used as a first-line drug in the treatment of MM in patients with serious RI. In conclusion, there are various research questions that can differentiate the treatment of patients with MM and RI in the near future.

Keywords: multiple myeloma, overall survival, renal involvement, BJP, impact.

References

1. van de Donk NWCJ, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397(10272):410-427.
2. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-E386.
3. Cancer Research UK: Myeloma Statistics.http://www.cancerresearchuk.org/healthprofessional/cancer-statistics/statistics-bycancer-type/myeloma (accessed October 13, 2015).
4. National Cancer Institute: SEER Cancer Statistics review, 1975–2008. 2011. http://seer.cancer.gov/archive/csr/1975_2008/index.html (accessed October 13, 2015).
5. Knudsen LM, Hjorth M, Hippe E. Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol. 2000;65(3):175-181.
6. Dimopoulos MA, Kastritis E, Rosinol L, Bladé J, Ludwig H. Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia. 2008;22(8):1485-1493.
7. Torra R, Bladé J, Cases A, et al. Patients with multiple myeloma requiring long-term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases. Br J Haematol. 1995;91(4):854-859.
8. International Myeloma Working Group: Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749-757.
9. Gonsalves WI, Leung N, Rajkumar SV, et al. Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma. Blood Cancer J. 2015;5(3):e296.
10. Delgado JC. Value of Urinary Free Light Chain Testing for Monitoring of Bence Jones Proteinuria. The journal of applied laboratory medicine. 2019;3(6):1059-1060.
11. Long Y, Aljamal AA, Bahmad HF, et al. Multiple myeloma presenting as acute tubulointerstitial nephritis. Autops Case Rep. 2021;11:e2021328.
12. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538-e548.
13. Voorhees PM, Jakubowiak AJ, Kumar SK, et al. Perspectives on Drug Development in Multiple Myeloma-Looking Forward to 2025. Clin Cancer Res. 2022;28(1):23-26.
14. Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95(5):548-567.
15. Bridoux F, Leung N, Belmouaz M, et al. Management of acute kidney injury in symptomatic multiple myeloma. Kidney Int. 2021;99(3):570-580.
16. Haynes RJ, Read S, Collins GP, Darby SC, Winearls CG. Presentation and survival of patients with severe acute kidney injury and multiple myeloma: a 20-year experience from a single centre. Nephrol Dial Transplant. 2010;25:419-426.
17. Hutchison CA, Cockwell P, Stringer S, Bradwell A, Cook M, Gertz MA, Dispenzieri A, Winters JL, Kumar S, Rajkumar SV, et al. Early reduction of serum-free light chains associates with renal recovery in myeloma kidney. J Am Soc Nephrol. 2011;22:1129–1136.
18. Basnayake K, Stringer SJ, Hutchison CA, Cockwell P. The biology of immunoglobulin free light chains and kidney injury. Kidney Int. 2011;79:1289–1301.
19. Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, Rekhtman G, Masliak Z, Robak T, Shubina A, et al: Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, noninferiority study. Lancet Oncol. 2011;12:431-440.
20. Martín-Reyes G, Toledo-Rojas R, Torres-de Rueda Á, et al. Haemodialysis using high cut-off dialysers for treating acute renal failure in multiple myeloma. Nefrologia. 2012;32(1):35-43.
21. Moreau P, Attal M, Hulin C, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet. 2019;394(10192):29-38.
22. Hutchison CA, Harding S, Mead G, et al. Serum free-light chain removal by high cutoff hemodialysis: optimizing removal and supportive care. Artif Organs. 2008;32(12):910-917.
23. Meng L, Gu G, Bi L. Transient receptor potential channels in multiple myeloma. Oncol Lett. 2022;23(4):108.
24. Yang Y, Li Y, Gu H, Dong M, Cai Z. Emerging agents and regimens for multiple myeloma. J Hematol Oncol. 2020;13(1):150.
25. Ludwig H, Drach J, Graf H, Lang A, Meran JG. Reversal of acute renal failure by bortezomib-based chemotherapy inpatients with multiple myeloma. Haematologica. 2007;92:1411–1414.
26. Roussou M, Kastritis E, Migkou M, Psimenou E, Grapsa I, Matsouka C, Barmparousi D, Terpos E, Dimopoulos MA. Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens. Leuk Lymphoma. 2008;49:890–895.
27. Long Y, Aljamal AA, Bahmad HF, et al. Multiple myeloma presenting as acute tubulointerstitial nephritis. Autops Case Rep. 2021;11:e2021328.